Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

Leukemia & lymphoma - 1 Feb 2019

Hu Bei, Thall Peter, Milton Denái R, Sasaki Koji, Bashir Qaiser, Shah Nina, Patel Krina, Popat Uday, Hosing Chitra, Nieto Yago, Lin Pei, Delgado Ruby, Jorgensen Jeffrey, Manasanch Elisabet, Weber Donna, Thomas Sheeba, Orlowski Robert Z, Champlin Richard, Qazilbash Muzaffar H

Abstract excerpt

The aim of our study was to determine the impact of high-risk disease (HRD) and MRD on outcomes in myeloma patients receiving bortezomib-based induction followed by autologous hematopoietic stem cell transplant (auto-HSCT). HRD included t(4:14), t(14;16), del 17p, del 1p and/or amplification 1q by cytogenetics/FISH; all others were standard-risk disease (SRD). A subset of 165 newly diagnosed myeloma patients in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Cytogenetic Analysis

Share to Hematopoietic Stem Cell Transplantation

Share to Multiple Myeloma

Share to Neoplasm, Residual

Share to Transplantation, Autologous

Source

Identifiers

PMID: 30032678
DOI: 10.1080/10428194.2018.1485908

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.PMID 30032678Read ↗

Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple MyelomaSemantic proximity Read ↗

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.Semantic proximity Read ↗

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationSemantic proximity Read ↗

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaSemantic proximity Read ↗

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisSemantic proximity Read ↗

Current Review on High-Risk Multiple Myeloma.Semantic proximity Read ↗

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Semantic proximity Read ↗

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.Semantic proximity Read ↗

Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched AnalysisSemantic proximity Read ↗

Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myelomaSemantic proximity Read ↗

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationSemantic proximity Read ↗

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.